Skip to main content

The Value of Phenotypic Precision Medicine in Prostate Cancer.

Publication ,  Journal Article
Hawkey, NM; Broderick, A; George, DJ; Sartor, O; Armstrong, AJ
Published in: Oncologist
February 8, 2023

Prostate cancer is the most common cancer among men and the second leading cause of cancer-related death. For patients who develop metastatic disease, tissue-based and circulating-tumor-based molecular and genomic biomarkers have emerged as a means of improving outcomes through the application of precision medicine. However, the benefit is limited to a minority of patients. An additional approach to further characterize the biology of advanced prostate cancer is through the use of phenotypic precision medicine, or the identification and targeting of phenotypic features of an individual patient's cancer. In this review article, we will discuss the background, potential clinical benefits, and limitations of genomic and phenotypic precision medicine in prostate cancer. We will also highlight how the emergence of image-based phenotypic medicine may lead to greater characterization of advanced prostate cancer disease burden and more individualized treatment approaches in patients.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Oncologist

DOI

EISSN

1549-490X

Publication Date

February 8, 2023

Volume

28

Issue

2

Start / End Page

93 / 104

Location

England

Related Subject Headings

  • Prostatic Neoplasms, Castration-Resistant
  • Prostatic Neoplasms
  • Precision Medicine
  • Oncology & Carcinogenesis
  • Male
  • Humans
  • Biomarkers, Tumor
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Hawkey, N. M., Broderick, A., George, D. J., Sartor, O., & Armstrong, A. J. (2023). The Value of Phenotypic Precision Medicine in Prostate Cancer. Oncologist, 28(2), 93–104. https://doi.org/10.1093/oncolo/oyac198
Hawkey, Nathan M., Amanda Broderick, Daniel J. George, Oliver Sartor, and Andrew J. Armstrong. “The Value of Phenotypic Precision Medicine in Prostate Cancer.Oncologist 28, no. 2 (February 8, 2023): 93–104. https://doi.org/10.1093/oncolo/oyac198.
Hawkey NM, Broderick A, George DJ, Sartor O, Armstrong AJ. The Value of Phenotypic Precision Medicine in Prostate Cancer. Oncologist. 2023 Feb 8;28(2):93–104.
Hawkey, Nathan M., et al. “The Value of Phenotypic Precision Medicine in Prostate Cancer.Oncologist, vol. 28, no. 2, Feb. 2023, pp. 93–104. Pubmed, doi:10.1093/oncolo/oyac198.
Hawkey NM, Broderick A, George DJ, Sartor O, Armstrong AJ. The Value of Phenotypic Precision Medicine in Prostate Cancer. Oncologist. 2023 Feb 8;28(2):93–104.

Published In

Oncologist

DOI

EISSN

1549-490X

Publication Date

February 8, 2023

Volume

28

Issue

2

Start / End Page

93 / 104

Location

England

Related Subject Headings

  • Prostatic Neoplasms, Castration-Resistant
  • Prostatic Neoplasms
  • Precision Medicine
  • Oncology & Carcinogenesis
  • Male
  • Humans
  • Biomarkers, Tumor
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis